Live Breaking News & Updates on Cardiamp cell therapy program

Stay informed with the latest breaking news from Cardiamp cell therapy program on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cardiamp cell therapy program and stay connected to the pulse of your community

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

California , United-states , Maryland , Peter-altman , Miranda-peto , David-mcclung , Centers-for-medicare-medicaid-services , Biocardia-inc , Exchange-commission-on , Cardiamp-cell-therapy-program , Maryland-stem-cell-research-fund , Heart-failure

BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K -December 18, 2023 at 07:02 am EST

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

SUNNYVALE, Calif. - December...

California , United-states , Maryland , Japan , Japanese , Peter-altman , Miranda-peto , David-mcclung , Device-agency-consultation-minutes , Medicaid-services , Exchange-commission-on , Biocardia-inc

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

SUNNYVALE, Calif., Dec. 18, 2023 -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced...

California , United-states , Maryland , Japan , Japanese , Miranda-peto , David-mcclung , Peter-altman , Device-agency , Medicaid-services , Cardiamp-cell-therapy-program , Biocardia-inc

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Maryland , United-states , Japan , California , Peter-altman , Biocardia-cardi , Miranda-peto , David-mcclung , Exchange-commission-on , Biocardia-inc , Centers-for-medicare , Device-agency

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval - BioCardia (NASDAQ:BCDA)

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an

Maryland , United-states , Japan , California , Miranda-peto , David-mcclung , Biocardia-cardi , Peter-altman , Cardiamp-cell-therapy-program , Device-agency , Maryland-stem-cell-research-fund , Biocardia-inc

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

United-states , Maryland , Minnesota , Peter-altman , Cardiamp-cell-therapy-program , Centers-for-medicare , Drug-administration , Biocardia-inc , Maryland-stem-cell-research-fund , Medicaid-services , Major-adverse-cardiovascular

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

California , United-states , Maryland , Minnesota , David-mcclung , Peter-altman , Miranda-peto , Centers-for-medicare , Cardiamp-cell-therapy-program , Drug-administration , Maryland-stem-cell-research-fund , Medicaid-services

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for ...

California , United-states , Maryland , Minnesota , Japan , Peter-altman , David-mcclung , Miranda-peto , Exchange-commission-on , Medicaid-services , Maryland-stem-cell-research-fund , Biocardia-inc

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy for Heart Failure (CardiAMP HF, clinicaltrials.gov Identifier: NCT02438306), for which the FDA granted Breakthrough Designation fo

Maryland , United-states , Wisconsin , Japan , University-of-wisconsin , California , Peter-altman , Carl-pepine , Miranda-peto , David-mcclung , Statistical-data-analysis-center , Exchange-commission-on

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial - BioCardia (NASDAQ:BCDA)

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today

Maryland , United-states , Wisconsin , California , University-of-wisconsin , Japan , Carl-pepine , David-mcclung , Miranda-peto , Peter-altman , Cardiamp-cell-therapy-program , National-principal-investigators